Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sports Nutrition Products Mark Start Of FDA’s Picamilon Enforcement

This article was originally published in The Tan Sheet

Executive Summary

Five warnings likely mark the start of a sweep to rid the US market of products containing the ingredient that the agency initially identified as violative in a recent declaration submitted for the Oregon attorney general’s complaint against GNC and that Senator McCaskill says FDA should prevent firms from using.

You may also be interested in...



Economic Adulteration Underscored In GAO Memory Supplements Study

Audit finds two of three memory supplements tested contain none or lower levels of active supplement than stated on labeling. In a report for current and previous  ranking minority members of Senate Special Committee on Aging, GAO points to continuing issues with economic adulteration for gingko biloba.

ProSupps Expands Picamilon Recall To 18 More Products

ProSupps initiates recall of fitness powders and drinks that contain picamilon, an unapproved ingredient that crosses the blood-brain barrier.

Regulatory Problems Mount For Supplement Firm Following Recall

in addition to distributing supplements containing ED ingredients, MS Bionic was in violation of an extensive list of supplement GMP regulations. Meanwhile Absonutrix makes claims for its herbals and botanicals including "aids in the inhibition of colon cancer cell growth and survival."

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel